U.S. stock market update: Immatics NV plummets 15.33%, $125 million underwriting issuance raises market concerns

U.S. Stock Market Midday Update Immatics NV fell 15.33%. Based on recent key news: On December 5, Immatics NV announced a $125 million underwritten offering. The company plans to sell 12,500,000 shares of common stock at a price of $10 per share, leading to a significant drop in stock price of 15.33%. Source: Reuters. The market's risk appetite for biotech stocks has decreased. Top Stocks by Trading Volume in the Industry Praxis Precision Medicines rose 41.91%. Based on recent key news: On December 5, Praxis Precision Medicines announced that its tremor drug ulixacaltamide received a New Drug Application (NDA) agreement from the U.S. FDA, causing the stock price to rise by 36%. This marks a significant advancement for the company in treating tremors, with potential approval expected in 2026. On December 5, the company prematurely ended an epilepsy study due to its significant efficacy, resulting in a 30% surge in stock price. This unexpected success further boosted market confidence in the company's drug development capabilities. On December 5, Praxis Precision Medicines reported positive mid-term results from the EMBOLD study, showing strong efficacy signals that support the NDA submission. This result is seen as a milestone in risk reduction, prompting analysts to raise the stock's target price. The biopharmaceutical industry has recently performed strongly, with noticeable capital inflows. Precision Science fell 0.04%. Based on recent news: On December 2, the early cancer screening market for digestive tract cancers in China is rapidly growing, driven by policy support for market expansion. With the release of the "Expert Consensus on Colorectal Cancer Screening for Community Residents in China," the penetration of molecular diagnostic technology in early screening for colorectal cancer has increased, promoting market development. On December 2, the project in Hanjing District adopted multi-gene methylation technology for blood tests for colorectal cancer, improving screening compliance and alleviating pressure on medical resources. This project provides a replicable and sustainable model for major chronic disease prevention and control in China, promoting the application of molecular diagnostic technology. On December 2, technological innovation is driving market expansion, with molecular diagnostic products changing the traditional screening landscape. Industry analysis indicates that the application of molecular diagnostic technology in early screening will further expand to other high-incidence cancers, creating economies of scale. The cancer early screening market is entering a golden development period. AbbVie fell 1.49%. Based on recent key news: On December 2, AbbVie presented new data on various blood cancer treatments at ASH 2025, highlighting advancements in T-cell engagers, BCL-2 inhibitors, and antibody-drug conjugates. These data demonstrated significant efficacy signals but also pointed out safety issues such as neutropenia and infections, which may affect investor confidence On December 5th, AbbVie's immunology business continued to perform strongly after losing patent protection for Humira, with sales of Skyrizi and Rinvoq increasing by 53% year-on-year to reach $18.5 billion, and expected to exceed $31 billion by 2027. This growth may boost market confidence in AbbVie's long-term prospects. On December 2nd, AbbVie announced a collaboration with Danish pharmaceutical company Gubra to develop the anti-obesity compound GUB014295, entering the weight management market. This move demonstrates the company's proactive strategy in expanding into new markets, which may impact stock price trends. Competition in the immunology field is intensifying and requires attention. Stocks Ranked Among the Top by Market Capitalization in the Industry Amgen fell by 2.03%. Based on recent key news: On December 4th, BMO Capital raised Amgen's target price from $335 to $372, maintaining an "Outperform" rating. This reflects analysts' continued confidence in the biotechnology group, driving stock price volatility. On December 3rd, Goldman Sachs reiterated its Buy rating on Amgen and set a target price of $400, expecting that key trial updates for its obesity drug MariTide will have a positive impact, enhancing market confidence. On December 4th, Amgen reported third-quarter results that exceeded expectations, primarily due to sales growth of Repatha and strong contributions from Prolia and rare disease drugs, raising its full-year guidance, leading investors to maintain an optimistic outlook for future growth. The biotechnology industry is facing drug price pressures, with significant capital inflows